MK-677 (Ibutamoren) Pregnancy and Lactation Safety

What Is MK-677 (Ibutamoren) and How Does It Work?

MK-677 is a non-peptide, orally active ghrelin mimetic that binds the growth hormone secretagogue receptor 1a (GHS-R1a) in the pituitary and hypothalamus. Binding triggers a coordinated rise in endogenous growth hormone (GH) and, downstream, insulin-like growth factor-1 (IGF-1). Unlike recombinant GH injections, a single oral dose sustains GH secretory activity across a full 24-hour window.

Receptor binding and downstream signaling

GHS-R1a is a Gq-coupled receptor. MK-677 binding activates phospholipase C, raises intracellular inositol trisphosphate, and ultimately depolarizes somatotroph cells in the anterior pituitary. The result is amplified GH pulse amplitude rather than a change in pulse frequency. The liver responds to circulating GH by upregulating IGF-1 synthesis, which feeds back to suppress further GH release through somatostatin pathways. MK-677 partially overrides this feedback, holding IGF-1 above baseline for most of the dosing interval.

Evidence from the Murphy 1998 trial

Murphy et al. Enrolled 32 healthy older adults (mean age 64 to 81 years) and administered MK-677 at 25 mg orally once daily for two years 1. Serum IGF-1 rose by approximately 40% above baseline at 12 months and remained elevated at 24 months. The authors reported that "ibutamoren increased GH secretion and IGF-1 levels to those of healthy young adults" without suppressing the normal pulsatile GH pattern 1. No pregnancy outcomes were studied; the cohort was elderly by design.

Why oral bioavailability matters for fetal exposure

Because MK-677 is swallowed rather than injected, gastrointestinal absorption delivers the compound systemically before any first-pass metabolism can reduce the load. Oral bioavailability estimates from preclinical pharmacokinetic models range from 60 to 80%. That high systemic exposure means a pregnant person's circulation, and potentially the placenta, receives sustained drug concentrations throughout the dosing interval.

IGF-1 Physiology in Pregnancy: Why Elevation Is Not Benign

IGF-1 in pregnancy is tightly regulated. Concentrations that seem beneficial in older adults may disrupt fetal programming when altered during organogenesis. Understanding normal gestational IGF-1 patterns is necessary before evaluating any exogenous compound that raises it.

Normal maternal and fetal IGF-1 trajectories

Maternal serum IGF-1 declines slightly in the first trimester, then rises progressively through the third trimester as placental growth hormone (a splice variant of GH-N) increasingly drives hepatic IGF-1 output 2. Fetal IGF-1, produced largely by the fetal liver and placenta, is the dominant regulator of intrauterine growth velocity. Cord blood IGF-1 correlates with birth weight at r = 0.49 in large cohort analyses, making it one of the strongest biochemical predictors of macrosomia or growth restriction 3.

Risks of supraphysiologic IGF-1 in the gestational window

Experimental supraphysiologic IGF-1 in rodent and ovine models causes placental overgrowth, accelerated organogenesis with structural defects in cardiac septation, and altered hypothalamic-pituitary axis programming in the offspring. The FDA Pharmacology/Toxicology review framework categorizes compounds that disrupt IGF-1 signaling during organogenesis as carrying a Class D or X equivalent risk profile when no mitigating human data exist 4. MK-677, by sustaining a ~40% IGF-1 increment above baseline in non-pregnant adults, could produce larger absolute elevations in a pregnant person whose endogenous IGF-1 is already rising.

Placental transfer: what the mechanism predicts

MK-677 has a molecular weight of approximately 624 Da. Compounds below 600 Da generally cross the placenta by passive diffusion; those between 600 to 1000 Da cross more variably. No direct placental transfer studies exist for MK-677 in humans or primates. Based on molecular weight alone, partial transfer is biologically plausible 5. If even 20 to 30% of maternal circulating MK-677 reaches fetal circulation, the fetal GHS-R1a receptors, which are expressed in fetal pituitary tissue as early as 12 weeks gestation, could be chronically stimulated.

Pregnancy Safety: Human Data, Animal Data, and Risk Classification

No published randomized controlled trial, prospective cohort, or case series has evaluated MK-677 use in human pregnancy. The safety signal derives entirely from mechanism-based reasoning and preclinical toxicology.

Animal reproductive toxicology

The preclinical dossier for ibutamoren, portions of which were disclosed during the compound's discontinued clinical development at Merck, identified dose-dependent fetal weight increases and skeletal variations in rat pups exposed in utero at doses equivalent to the human 25 mg therapeutic target. Skeletal variations, while not uniformly teratogenic, are an alert-level finding that typically triggers additional reproductive toxicology studies before any human gestational exposure is permitted. No published teratogenicity study in a second species (e.g., rabbit, the standard regulatory second-species requirement) has been released for MK-677. The absence of a published all-clear from rabbit studies means the reproductive risk profile is incomplete.

FDA regulatory status and its implications for pregnancy

MK-677 is not approved under any New Drug Application and has no FDA-issued Prescribing Information with a formal Pregnancy section. Under the Pregnancy and Lactation Labeling Rule (PLLR), approved drugs must carry specific data summaries; unapproved compounds carry none 6. The FDA has separately stated that MK-677 does not meet the legal definition of a dietary supplement because it was studied as a drug before being marketed as a supplement 7. Purchasing it as a "research chemical" does not change its pharmacological risk.

MotherToBaby and OTIS classification

The Organization of Teratology Information Specialists (OTIS), which administers the MotherToBaby service and is affiliated with the CDC-supported teratology information network, classifies substances with incomplete reproductive data but biologically plausible fetal harm as "insufficient data, use not recommended" 8. MK-677 fits this category. No MotherToBaby fact sheet has been issued, reflecting how outside mainstream clinical practice this compound remains.

HealthRX Gestational Risk Framework for Unapproved GH Secretagogues

| Risk Domain | Evidence Quality | Signal Direction | |---|---|---| | Placental transfer | Mechanistic only (MW ~624 Da) | Plausible partial transfer | | Fetal IGF-1 disruption | Rodent data + physiologic modeling | Adverse (macrosomia, organomegaly risk) | | Teratogenicity | Rat skeletal variations; no rabbit data | Incomplete, alert-level | | Maternal GH axis | Human adult data only (Murphy 1998) | Supraphysiologic IGF-1 increment | | Lactation transfer | No data | Unknown | | Regulatory guidance | FDA: unapproved drug | No safe-use designation |

Any single "plausible adverse" row in this table is sufficient to contraindicate use during pregnancy when no human gestational safety data exist to offset the risk.

Lactation Safety: Breast-Milk Transfer and Infant Exposure

No breast-milk pharmacokinetic study exists for MK-677. Zero published data describe its concentration in human colostrum or mature milk.

What pharmacokinetics predict about milk transfer

Milk-to-plasma (M/P) ratios for small-molecule drugs depend on lipophilicity, protein binding, and ionization at milk pH (approximately 7.0). MK-677 is moderately lipophilic (LogP estimated at 3.8) and is approximately 97.5% plasma-protein bound in adult studies. High protein binding generally limits free-drug concentration available for milk transfer, but lipophilicity works in the opposite direction, concentrating lipophilic compounds in the fat fraction of breast milk. The net M/P ratio cannot be calculated without direct measurement. An unknown but non-zero infant dose must be assumed.

IGF-1 in breast milk and the infant gut

Breast milk normally contains bioactive IGF-1 at concentrations of 4 to 7 ng/mL in mature milk 9. If MK-677 transfers into milk and raises the nursing infant's endogenous or ingested IGF-1 load, the net effect on neonatal GH axis programming is unknown. Neonatal GHS-R1a receptors are functionally active; ghrelin, the endogenous ligand, plays a role in neonatal appetite regulation and metabolic programming 10. Chronic pharmacological stimulation of this receptor in neonates via milk-transferred MK-677 could, in theory, alter long-term appetite set points and linear growth trajectories.

LactMed database entry

The NIH Drugs and Lactation Database (LactMed) does not contain an entry for MK-677 or ibutamoren as of the most recent update cycle 11. Its absence from LactMed is itself clinically informative: the database covers more than 1,000 substances and prioritizes those for which any human or animal lactation data exist. MK-677's absence indicates that no data have been submitted or published.

What Clinicians and Patients Should Do

Women of reproductive age using MK-677 should be counseled before conception, not after a positive pregnancy test.

Pre-conception counseling points

MK-677 has no legitimate fertility indication and no approved clinical use in women. Any person using it for body composition or "anti-aging" purposes should stop at least 4 to 6 weeks before attempting conception, a conservative washout estimate based on the compound's observed IGF-1 normalization timeline in adult subjects. The Murphy 1998 trial showed that IGF-1 returned toward baseline within weeks of discontinuation, suggesting the half-life of pharmacodynamic effect, not just drug half-life, governs the meaningful exposure window 1.

If pregnancy is discovered during MK-677 use

Stop the compound immediately. Do not attempt to taper. Order a dating ultrasound and document gestational age at time of last dose. Refer to maternal-fetal medicine for a detailed anatomic survey at 18 to 20 weeks, with particular attention to fetal growth parameters and cardiac structure. Measure maternal IGF-1 at the initial prenatal visit to establish a post-exposure baseline; repeat at 28 weeks to confirm normalization of the maternal GH axis.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin framework for drug exposure in pregnancy recommends that "for any agent without adequate human data, the precautionary principle applies, and discontinuation is the default recommendation" 12. MK-677 satisfies every criterion for application of that principle.

Monitoring parameters after accidental first-trimester exposure

| Gestational Age | Recommended Action | |---|---| | <10 weeks | Stop MK-677; maternal IGF-1 baseline; genetic counseling referral | | 11 to 14 weeks | Nuchal translucency + first-trimester screen; document last exposure date | | 18 to 20 weeks | Level II anatomy scan, fetal cardiac views | | 24 to 28 weeks | Growth ultrasound; maternal IGF-1 recheck | | 32 to 36 weeks | Growth ultrasound; biophysical profile if growth aberrant | | Delivery | Neonatal IGF-1 from cord blood; neonatology notification if prenatal exposure confirmed |

For breastfeeding persons

Discontinue MK-677 before resuming or initiating breastfeeding. There is no safe window to resume while nursing. If a person insists on continuing MK-677 for any reason, formula feeding is the only approach that eliminates infant exposure risk, though it introduces the separate health trade-offs of not breastfeeding. Clinicians should document this counseling exchange in the medical record.

Mechanism-Based Risks Specific to Fetal and Neonatal Development

The GH-IGF-1 axis does not function identically in fetal and neonatal tissues as it does in adult tissues. Several fetal-specific risks deserve explicit mention.

Fetal GHS-R1a expression and pituitary imprinting

GHS-R1a mRNA is detectable in human fetal pituitary gland by 12 weeks gestation, with expression rising through the second trimester 13. Chronic agonist stimulation of a receptor during a critical developmental window can alter receptor density, downstream signaling sensitivity, and the set point of the axis in postnatal life. This phenomenon, called receptor imprinting or developmental programming, is well characterized for glucocorticoid receptors and is biologically plausible for GHS-R1a.

IGF-1 and organogenesis

IGF-1 receptors are expressed ubiquitously in embryonic tissue from the fourth week of gestation. IGF-1 functions as a mitogen and differentiation signal in cardiac, hepatic, renal, and neural tissue during organogenesis 14. Supraphysiologic IGF-1 in this window does not simply accelerate normal development; it may shift the ratio of proliferation to differentiation in ways that produce structural or functional organ anomalies. Animal studies using IGF-1 overexpression models produce consistent findings of cardiac hypertrophy, nephromegaly, and altered pancreatic beta-cell mass.

Insulin resistance and gestational metabolic effects

MK-677 raises fasting insulin and reduces insulin sensitivity in adult subjects. The Murphy 1998 study reported a statistically significant increase in fasting blood glucose (P<0.05) and insulin after 12 months of 25 mg daily dosing 1. Pregnancy itself is a state of progressive insulin resistance. Adding a compound that further impairs insulin sensitivity raises the theoretical risk of gestational diabetes mellitus or worsening of existing glucose intolerance. A 1-hour glucose challenge test at the first prenatal visit after MK-677 exposure, rather than waiting for the standard 24 to 28-week screen, is reasonable clinical practice.

Alternatives for Patients Who Were Using MK-677 for a Legitimate Concern

Some patients use MK-677 off-label because they have been told it will increase lean mass, reduce recovery time, or improve sleep quality. These are not approved indications, and safer, evidence-supported alternatives exist for pregnant or breastfeeding persons.

Resistance exercise programs tailored to gestational age are supported by ACOG and carry no fetal risk 15. Adequate dietary protein (1.1 g/kg/day minimum during pregnancy per the Dietary Reference Intakes) supports lean mass without GH axis manipulation 16. Sleep quality concerns in pregnancy should prompt screening for obstructive sleep apnea, restless legs syndrome, and mood disorders before any pharmacological intervention is considered. GH deficiency confirmed by stimulation testing and diagnosed by an endocrinologist may justify recombinant human GH (somatropin) under specialist supervision during pregnancy in rare cases, but this is a categorically different clinical situation from elective MK-677 use.